ライフサイエンスコーパス: MERS

1 MERS-CoV antibodies were detected in 13 of 24 (54%) case

2 MERS-CoV infection failed to elicit robust IFN response,

3 MERS-CoV remains a high-threat pathogen identified by WH

4 MERS-CoV replication significantly upregulated C-type le

5 MERS-CoV seronegative and seropositive camels received a

6 MERS-CoV was first identified in June 2012 and has since

7 hermal calorimetry showed an approximate 1:1 MERS-CoV FP to Ca(2+) ratio, as opposed to an 1:2 SARS-C

8 ion of antibodies to SARS-CoV-2, SARS-CoV-1, MERS, three circulating coronavirus strains (HKU1, 229E,

9 th coronavirus infection (defined as SARS-1, MERS, SARS-CoV-2, and other coronavirus) and bacterial/f

10 eutralizing antibodies cross-neutralizing 17 MERS pseudoviruses expressing S proteins of representati

11 other acute respiratory syndromes (COVID-19, MERS, and SARS).

12 Of 349 MERS patients, 144 (41.3%) patients received RBV/rIFN (R

13 e of AgNPs, giving detection limits of 1.53 (MERS-CoV), 1.27 (MTB), and 1.03 nM (HPV).

14 rability, and immunogenicity of the GLS-5300 MERS coronavirus DNA vaccine in healthy adults.

15 The GLS-5300 MERS coronavirus vaccine was well tolerated with no vacc

16 und that the spike protein of PDF2180-CoV, a MERS-like virus found in a Ugandan bat, could mediate in

17 of remdesivir treatment in the context of a MERS clinical trial.

18 ctious camels with active naturally acquired MERS-CoV infection, were co-housed with the vaccinated c

19 n control are required to prevent additional MERS outbreaks.

20 After MERS-CoV challenge, both vaccines conferred complete pro

21 There are no treatment options against MERS-CoV for humans or animals, and there are no large-s

22 otein induce potent immune responses against MERS-CoV and RABV.

23 -scale clinical trials for therapies against MERS-CoV.

24 re no efficacious drugs and vaccines against MERS-CoV, increasing its potential to cause a public hea

25 Although MERS-CoV generally causes subclinical or mild disease, i

26 miological investigation was conducted among MERS-CoV case patients (cases) and their household conta

27 s well as the closely related SARS-CoV-1 and MERS coronaviruses, is restricted to BSL-3 facilities.

28 ple CoVs, including SARS-CoV, SARS-CoV-2 and MERS-CoV.

29 is important for IKKepsilon activation, and MERS-CoV ORF8b suppresses type I IFN expression by compe

30 we tested the hypothesis that bat cells and MERS coronavirus (CoV) can co-exist in vitro.

31 SARS-CoV and MERS-CoV FPs share a high sequence homology, and here, w

32 Both SARS-CoV and MERS-CoV have caused serious outbreaks and epidemics in

33 h two major outbreaks caused by SARS-CoV and MERS-CoV in the year 2002 and 2012, respectively.

34 st SARS-CoV-2 that also inhibit SARS-CoV and MERS-CoV in vitro We found that 17 of these inhibit SARS

35 vancements made by studying the SARS-CoV and MERS-CoV outbreaks have provided a foundation for unders

36 developed in response to prior SARS-CoV and MERS-CoV outbreaks that can serve as resources for devel

37 structurally characterized the SARS-CoV and MERS-CoV S glycoproteins in complex with neutralizing an

38 ronaviruses that are related to SARS-CoV and MERS-CoV were discovered in bats worldwide.

39 her beta-coronaviruses, such as SARS-CoV and MERS-CoV, and might become an important tool for structu

40 with the related coronaviruses SARS-CoV and MERS-CoV, and the vast experience with other common RNA

41 ighly pathogenic coronaviruses, SARS-CoV and MERS-CoV, have been controversial in terms of their prot

42 iratory tract illnesses, except SARS-CoV and MERS-CoV, which, in addition to mild illness can also be

43 The search terms also included SARS-CoV and MERS-CoV.

44 hCoVs 229E, NL63, OC43, HKU1, SARS-CoV, and MERS-CoV.

45 cus on seasonal coronaviruses, SARS-CoV, and MERS-CoV.

46 ructures that were antiviral against IAV and MERS-CoV along with the filoviruses Ebola and Marburg an

47 f SKI genes inhibited replication of IAV and MERS-CoV.

48 mutations across the genome in both MHV and MERS-CoV.

49 coronavirus, mouse hepatitis virus (MHV) and MERS-CoV, encode 2',5'-phosphodiesterases (2',5'-PDEs) t

50 iation of RBV/rIFN with 90-day mortality and MERS coronavirus (MERS-CoV) RNA clearance using marginal

51 of evolutionary rates based on HCoV-OC43 and MERS-CoV.

52 In contrast to DENV, SARS and MERS CoVs predominantly infect respiratory epithelium, n

53 y pathogenic coronaviruses such as SARS- and MERS-CoV into human circulation.

54 Incorporation of CD40L into rAd5-based MERS-CoV S1 vaccine targeting molecule and molecular adj

55 sing concerns over the efficacy of RBD-based MERS vaccines against circulating human and camel MERS-C

56 N retention signal by using chimeras between MERS-CoV M and the M protein of infectious bronchitis vi

57 Sera were screened by MERS-CoV nucleocapsid protein enzyme-linked immunosorben

58 in the RBD of representative human and camel MERS-CoV strains during the 2012-2015 outbreaks.

59 S proteins of representative human and camel MERS-CoV strains identified during the 2012-2015 outbrea

60 ion by divergent circulating human and camel MERS-CoV strains.

61 vaccines against circulating human and camel MERS-CoV strains.

62 eived a single intramuscular dose of ChAdOx1 MERS, a replication-deficient adenoviral vectored vaccin

63 cally ill patients with laboratory-confirmed MERS from 14 hospitals in Saudi Arabia diagnosed between

64 ospitalized adults with laboratory-confirmed MERS were randomly assigned to receive recombinant inter

65 been hospitalized with laboratory-confirmed MERS.

66 ll shape the capacity to prevent and control MERS-CoV or new emerging disease transmission.

67 then analyzed the ability of mice to control MERS-CoV infection.

68 respiratory syndrome-associated coronavirus (MERS-CoV).

69 734) effectively inhibited MERS coronavirus (MERS-CoV) replication in vitro, and showed efficacy agai

70 with 90-day mortality and MERS coronavirus (MERS-CoV) RNA clearance using marginal structural modeli

71 ory syndrome and was named MERS coronavirus (MERS-CoV).

72 S-CoV), Middle East respiratory coronavirus (MERS-CoV) and SARS-CoV-2, have been linked back to vario

73 iddle East respiratory syndrome coronavirus (MERS-CoV) and severe acute respiratory syndrome coronavi

74 iddle East respiratory syndrome coronavirus (MERS-CoV) are two highly transmissible and pathogenic vi

75 iddle East respiratory syndrome coronavirus (MERS-CoV) binds to cellular receptor dipeptidyl peptidas

76 iddle East respiratory syndrome coronavirus (MERS-CoV) causes severe and often lethal respiratory ill

77 iddle East respiratory syndrome coronavirus (MERS-CoV) emerged in 2012 and is a highly pathogenic res

78 iddle East respiratory syndrome coronavirus (MERS-CoV) has been attributed to overcrowding, delayed d

79 iddle East respiratory syndrome coronavirus (MERS-CoV) has been shown to infect both humans and drome

80 iddle East respiratory syndrome coronavirus (MERS-CoV) have revealed that delayed chain termination i

81 iddle East respiratory syndrome coronavirus (MERS-CoV) in household and healthcare settings, more dat

82 iddle East respiratory syndrome coronavirus (MERS-CoV) infection have been reported worldwide, with 6

83 iddle East respiratory syndrome coronavirus (MERS-CoV) infections are still unknown.

84 iddle East respiratory syndrome coronavirus (MERS-CoV) infections pose threats to public health world

85 iddle East respiratory syndrome coronavirus (MERS-CoV) initially emerged in 2012 and has since been r

86 iddle East respiratory syndrome coronavirus (MERS-CoV) is a highly pathogenic human coronavirus causi

87 iddle East respiratory syndrome coronavirus (MERS-CoV) is a highly pathogenic respiratory virus that

88 iddle East respiratory syndrome coronavirus (MERS-CoV) is a lethal zoonotic pathogen endemic to the A

89 iddle East respiratory syndrome coronavirus (MERS-CoV) is a lethal zoonotic pathogen that was first i

90 iddle East respiratory syndrome coronavirus (MERS-CoV) is a lineage C betacoronavirus that since its

91 iddle East respiratory syndrome coronavirus (MERS-CoV) is a major emerging infectious disease with zo

92 iddle East respiratory syndrome coronavirus (MERS-CoV) is an emerging human pathogen that is the caus

93 iddle East respiratory syndrome coronavirus (MERS-CoV) is an important emerging pathogen that was fir

94 iddle East respiratory syndrome coronavirus (MERS-CoV) is the causative agent of a severe respiratory

95 iddle East respiratory syndrome coronavirus (MERS-CoV) M protein.

96 iddle East respiratory syndrome coronavirus (MERS-CoV) multiplication results in reduced BECN1 levels

97 iddle East respiratory syndrome coronavirus (MERS-CoV) ORF4a accessory gene is expressed in yeast it

98 iddle East respiratory syndrome coronavirus (MERS-CoV) poses a threat to public health.

99 iddle East respiratory syndrome coronavirus (MERS-CoV) poses an ongoing threat to public health world

100 iddle East respiratory syndrome coronavirus (MERS-CoV) utilizes dipeptidyl peptidase 4 (DPP4) as an e

101 iddle East respiratory syndrome coronavirus (MERS-CoV) vaccines.

102 iddle East respiratory syndrome coronavirus (MERS-CoV) with eukaryotic proteins that may be potential

103 iddle East respiratory syndrome coronavirus (MERS-CoV), and human CoV 229E (HCoV-229E).

104 iddle East respiratory syndrome coronavirus (MERS-CoV), and the most recently emerged SARS-CoV-2.

105 iddle East respiratory syndrome coronavirus (MERS-CoV), encode a papain-like protease (PLpro) that po

106 iddle East respiratory syndrome coronavirus (MERS-CoV), from less pathogenic coronaviruses.

107 iddle East respiratory syndrome coronavirus (MERS-CoV), Mycobacterium tuberculosis (MTB), and human p

108 iddle East respiratory syndrome coronavirus (MERS-CoV), the spike (S) protein is the main determinant

109 iddle East respiratory syndrome coronavirus (MERS-CoV), two other highly pathogenic coronavirus spill

110 iddle East respiratory syndrome coronavirus (MERS-CoV).

111 iddle East respiratory syndrome coronavirus (MERS-CoV).

112 iddle East respiratory syndrome coronavirus (MERS-CoV).

113 iddle East respiratory syndrome coronavirus (MERS-CoV).

114 iddle East respiratory syndrome coronavirus (MERS-CoV).

115 iddle East respiratory syndrome coronavirus (MERS-CoV).

116 iddle East respiratory syndrome coronavirus (MERS-CoV).IMPORTANCE Genetic recombination is often demo

117 iddle East respiratory syndrome coronavirus (MERS-CoV); however, development of effective and safe hu

118 M) and Middle East respiratory syndrome CoV (MERS-CoV) (EC(50) = 0.56 muM) with minimal cytotoxicity.

119 oV) or Middle East respiratory syndrome CoV (MERS-CoV) also use bacterial components to modulate infe

120 2) and Middle East respiratory syndrome CoV (MERS-CoV) within two decades(1-3).

121 CoV-2, Middle East respiratory syndrome CoV (MERS-CoV), bat CoV HKU5 expressing the SARS-CoV-1 spike,

122 V) and Middle East respiratory syndrome CoV (MERS-CoV).

123 a-CoVs Middle East respiratory syndrome-CoV (MERS-CoV) and SARS-CoV and the gamma-CoV infectious bron

124 SARS-CoV-2 as well as the related SARS-CoV, MERS-CoV and endemic human coronaviruses (HCoVs).

125 erefore, the activity of PLPs from SARS-CoV, MERS-CoV, and mouse hepatitis virus was evaluated agains

126 ays, and cytokine secretion during SARS-CoV, MERS-CoV, and SARS-CoV-2 infection.

127 ined almost identical results with SARS-CoV, MERS-CoV, and SARS-CoV-2 RdRps.

128 coronavirus infection (SARS-CoV-2, SARS-CoV, MERS-CoV, seasonal coronaviruses).

129 uch as camels, as well as humans from deadly MERS-CoV and RABV infections.

130 V-HKU1) as well as severe illness and death (MERS-CoV, SARS-CoV, SARS-CoV-2).

131 ng recombinant wild-type and ORF8b-deficient MERS-CoV further confirmed the suppressive role of ORF8b

132 at were persistently infected with DeltaORF5 MERS-CoV were resistant to superinfection by wildtype vi

133 We now demonstrate that in addition to DPP4, MERS-CoV binds to sialic acid (Sia).

134 monstrate that intracellular Ca(2+) enhances MERS-CoV wild-type (WT) PP infection by approximately 2-

135 MERS-CoV strains, as well as antibody escape MERS-CoV mutants.

136 during the 2012-2015 outbreaks, 5 MAb escape MERS-CoV mutants, and 2 live human MERS-CoV strains.

137 cts and depletion of macrophages exacerbates MERS-CoV-induced pathology and clinical symptoms of dise

138 y provides a structural framework explaining MERS-CoV attachment to sialoside receptors and identifie

139 cient adenoviral vectored vaccine expressing MERS-CoV spike protein, with further groups receiving co

140 h reduction in 90-day mortality or in faster MERS-CoV RNA clearance.

141 No therapeutics or vaccines are approved for MERS; thus, development of novel therapies is needed.

142 efficacy of GLS-5300 in a region endemic for MERS coronavirus.

143 via a conserved groove that is essential for MERS-CoV S-mediated attachment to sialosides and entry i

144 rst time that SIRT1 is a proviral factor for MERS-CoV replication and that ORF4a has a role in modula

145 rst time that SIRT1 is a proviral factor for MERS-CoV replication and that ORF4a has a role in modula

146 ggesting that SIRT1 is a proviral factor for MERS-CoV.

147 lization, namely TGN and ERGIC/cis-Golgi for MERS-M and IBV-M, respectively.

148 ecombinant (r)shDPP4 as an effective MCM for MERS infection.

149 The role of Mincle for MERS-CoV-triggered cytokine/chemokine induction was esta

150 tential of rshDPP4 as a treatment option for MERS.

151 World Health Organization questionnaire for MERS-CoV case-control studies to assess risk factors for

152 r ability to act as functional receptors for MERS-CoV.

153 investigated whether Ca(2+) is required for MERS-CoV fusion by screening a mutant array in which E a

154 r acts as a delayed RNA chain terminator for MERS-CoV polymerase complexes.

155 There are no approved treatments for MERS-CoV infection although a combination of lopinavir,

156 e, we applied technology previously used for MERS-CoV to produce a prefusion-stabilized SARS-CoV-2 sp

157 es reveal that removing the Ubl2 domain from MERS PLpro has no effect on its ability to process the v

158 ation by monoclonal antibodies and sera from MERS patients.

159 ental vaccine vector BNSP333, and the RABV G-MERS-CoV S1 fusion protein was efficiently expressed and

160 CD40-mediated specific responses to generate MERS-CoV S1 subunit-based vaccine.

161 on prevention and control measures for human MERS-CoV infections.

162 rol studies to assess risk factors for human MERS-CoV seropositivity at a farm complex in Qatar.

163 Ab escape MERS-CoV mutants, and 2 live human MERS-CoV strains.

164 therapy was commonly used in critically ill MERS patients but was not associated with reduction in 9

165 Our data illuminate MERS-CoV S sialoside specificity and suggest that select

166 DPP4 species-specific differences impacting MERS-CoV host range and better inform our understanding

167 aling species-specific differences impacting MERS-CoV host range.

168 ls expressing high levels of DPP4.IMPORTANCE MERS-CoV has pandemic potential, and it is important to

169 emergence and host susceptibility.IMPORTANCE MERS-CoV is a recently emerged zoonotic virus that is st

170 ORF8b was abundantly expressed in MERS-CoV-infected Huh-7 cells.

171 ontribute to the proinflammatory response in MERS-CoV-infected macrophages.

172 Substitution of this motif resulted in MERS-CoV M leakage toward the plasma membrane.

173 that the serum shDPP4 levels play a role in MERS pathogenesis and demonstrate a potential of rshDPP4

174 ent could be attributed to Ca(2+) increasing MERS-CoV FP fusion-relevant membrane ordering.

175 Remdesivir (GS-5734) effectively inhibited MERS coronavirus (MERS-CoV) replication in vitro, and sh

176 induced clinical disease, strongly inhibited MERS-CoV replication in respiratory tissues, and prevent

177 ace Sia by neuraminidase treatment inhibited MERS-CoV entry of Calu-3 human airway cells, thus provid

178 There are as yet no licensed MERS vaccines or therapeutics.

179 infection by divergent pseudotyped and live MERS-CoV strains, as well as antibody escape MERS-CoV mu

180 Further, since many MERS cases are acquired in healthcare settings, public h

181 ddle East respiratory syndrome and was named MERS coronavirus (MERS-CoV).

182 These VHHs neutralize MERS-CoV or SARS-CoV-1 S pseudotyped viruses, respective

183 d and characterized type I IFN antagonism of MERS-CoV open reading frame (ORF) 8b accessory protein.

184 ns designated S1(A) through S1(D) Binding of MERS-CoV to the cell surface entry receptor dipeptidyl p

185 ber 2019, 2499 laboratory-confirmed cases of MERS-CoV infection, including 858 deaths (34.3% mortalit

186 We conclude that the catalytic core of MERS PLpro, i.e. without the Ubl2 domain, is sufficient

187 No serologic evidence of MERS-CoV transmission was found among 105 household cont

188 s not required for the catalytic function of MERS PLpro in vitro.

189 By sequencing the whole genome of MERS-CoV from persistently infected bat cells, we identi

190 Although the overall impact of MERS-CoV PLpro function is observed to be essential, dif

191 Despite frequent imports of MERS-CoV with camels from Africa, African lineages of ME

192 tein to study the mechanism of inhibition of MERS-CoV RdRp by RDV.

193 ant differences in FP Ca(2+) interactions of MERS-CoV and SARS-CoV FP despite their high sequence sim

194 As a result, the interface of MERS-CoV and human interferon-stimulated gene product 15

195 The introduction of MERS-CoV into the Republic of Korea by an infected trave

196 termined values of 50% lethal dose (LD50) of MERS-CoV for the 2 strains of mice, compared and correla

197 with camels from Africa, African lineages of MERS-CoV do not establish themselves in Saudi Arabia.

198 vir treatment in a nonhuman primate model of MERS-CoV infection, the rhesus macaque.

199 Therefore, development of mouse models of MERS-CoV has been hampered by the fact that MERS-CoV doe

200 n the course of a large hospital outbreak of MERS in the Republic of Korea in 2015, the spread of a v

201 traveler resulted in a hospital outbreak of MERS that entailed 186 cases and 38 deaths.

202 The recent outbreaks of MERS and previous emerging infections provide valuable l

203 munity clusters, and nosocomial outbreaks of MERS-CoV continue to occur.

204 tissues contribute to high pathogenicity of MERS-CoV.

205 We determined the prevalence of MERS-CoV infection, age-associated patterns of infection

206 autophagy but also reduce the replication of MERS-CoV up to 28,000-fold.

207 related activities may pose a higher risk of MERS-CoV infection, as may cross-border movements of cam

208 2,3-linked Sias and the predominant sites of MERS-CoV replication in the upper and lower respiratory

209 The studies of MERS patients with severe disease and experimentally inf

210 lable vaccines or therapeutics, the study of MERS-CoV pathogenesis is crucial for its control and pre

211 Transmission of MERS-CoV was not documented in this investigation of mos

212 tivorous bats, suggests that transmission of MERS-like-CoVs mainly occurs via the fecal-oral route.

213 included previous infection or treatment of MERS.

214 health worldwide, making an understanding of MERS pathogenesis and development of effective medical c

215 COVID-19, 5/18 (28%) on SARS-1, 1/18 (6%) on MERS, and 3/18 (17%) on other coronaviruses.

216 al a specific area of high glycan density on MERS S that results in the formation of oligomannose-typ

217 (+) T cells, or macrophages has no effect on MERS-CoV replication in the lungs of infected mice.

218 nsgenic mice to study the effect of hDPP4 on MERS-CoV infection.

219 on the current knowledge and perspectives on MERS epidemiology, virology, mode of transmission, patho

220 s for characterizing the effect of shDPP4 on MERS pathogenesis.

221 e closely related coronavirus, SARS-CoV-1 or MERS-CoV, despite previous zoonotic outbreaks.

222 ive virus challenge of animals given SARS or MERS vaccines resulted in vaccine hypersensitivity react

223 d the possibility that the zoonotic pathogen MERS-CoV, which also cocirculates in the same camel spec

224 After adjusting for age, epidemic period, MERS patients with comorbidity had around 4 times the ri

225 arked pulmonary perivascular hemorrhage post-MERS-CoV challenge despite the observed protection.

226 pectrum RBD-based subunit vaccine to prevent MERS-CoV infection.

227 h prior to inoculation completely prevented MERS-CoV-induced clinical disease, strongly inhibited ME

228 domain of the MERS-CoV nucleocapsid protein (MERS-CoV N-NTD).

229 Therefore, we developed a RABV-MERS vector that contained the MERS-CoV S1 domain of the

230 hese data establish that an inactivated RABV-MERS S-based vaccine may be effective for use in animals

231 {CI}, .73-1.44]; P = .87) or with more rapid MERS-CoV RNA clearance (adjusted hazard ratio, 0.65 [95%

232 l or genetic manipulation, there was reduced MERS-CoV replication, suggesting that SIRT1 is a provira

233 for the inflammatory response in regulating MERS-CoV pathogenesis in vivo The Middle East respirator

234 The FSE-arch is conserved in the related MERS-CoV and is under purifying selection.

235 tion with the PDF2180 spike does not require MERS-CoV receptor DPP4 and antibodies developed against

236 SARS, MERS, Ebola, Nipah and an array of arenavirus infections

237 Disease outbreaks such as SARS, MERS, Swine Flu, Ebola, and COVID-19 (on-going) have cau

238 infected cells expressing coronavirus (SARS, MERS) spike as a biosecure alternative to assays involvi

239 from 65 research articles on POCTs of SARS, MERS and COVID-19.

240 uman coronaviruses (229E/OC43/NL63/HKU1/SARS/MERS), human enteroviruses/rhinoviruses, measles virus,

241 stently infected cell culture model to study MERS-CoV-bat interactions.

242 While bat, camel, and human DPP4 support MERS-CoV infection, several DPP4 orthologs, including mo

243 (SARS) and Middle East respiratory syndrome (MERS) are speculated to have originated in bats.

244 outcome of Middle East respiratory syndrome (MERS) cases up to the end of October 2016.

245 ergence of Middle East Respiratory Syndrome (MERS) cases with a high case fatality rate stresses the

246 Middle East respiratory syndrome (MERS) coronavirus causes a highly fatal lower-respirator

247 n (RBD) of Middle East respiratory syndrome (MERS) coronavirus spike, mediates viral entry using pseu

248 virus, and Middle East respiratory syndrome (MERS) coronavirus.

249 (SARS) and Middle East respiratory syndrome (MERS) coronaviruses (CoVs) are zoonotic pathogens with h

250 The Middle East respiratory syndrome (MERS) emerged in Saudi Arabia in 2012, caused by a zoono

251 lized with Middle East respiratory syndrome (MERS) is unclear.

252 number of Middle East respiratory syndrome (MERS) outbreaks have been linked to healthcare facilitie

253 (SARS) and Middle East respiratory syndrome (MERS)(4,5).

254 ients with Middle East respiratory syndrome (MERS), accounting for time-varying confounders.

255 -CoV-1 and Middle East respiratory syndrome (MERS), the development of therapeutic antibodies and vac

256 S)-CoV and Middle East respiratory syndrome (MERS)-CoV are epidemic zoonotic CoVs that emerged at the

257 ion of two Middle East respiratory syndrome (MERS)-like bat CoVs using exogenous protease treatment.

258 agent for Middle East respiratory syndrome (MERS).

259 me-CoV and Middle East respiratory syndrome (MERS-CoV).

260 ., SARS-1, Middle East respiratory syndrome [MERS]).

261 Therefore, this study demonstrates that MERS-CoV RBD is an important vaccine target able to indu

262 MERS-CoV has been hampered by the fact that MERS-CoV does not replicate in commonly available mouse

263 Our findings indicate that MERS-CoV M protein localizes to the TGN because of the c

264 These findings indicate that MERS-CoV variants with reduced neutralization sensitivit

265 The MERS-CoV spike (S) protein binds to the cellular protein

266 The MERS-CoV-induced proinflammatory response was evaluated

267 or DPP4 and antibodies developed against the MERS spike receptor-binding domain and S2 portion are in

268 We identify a functional link between the MERS-CoV ORF4a proteins and the YDL042C/SIR2 yeast gene.

269 eloped a RABV-MERS vector that contained the MERS-CoV S1 domain of the MERS-CoV S protein fused to th

270 ivated rabies virus particles containing the MERS-CoV S1 protein induce potent immune responses again

271 ivated rabies virus (RABV) that contains the MERS-CoV spike (S) protein expressed on its surface.

272 icted to infection at the level of DPP4, the MERS-CoV receptor, we generated mice with humanized exon

273 During the MERS outbreak in Korea, emergence and spread of viral va

274 Here, we co-expressed the MERS-CoV nonstructural proteins nsp5, nsp7, nsp8, and ns

275 ting with negatively charged residues in the MERS-CoV FP region.

276 utant array in which E and D residues in the MERS-CoV FP were substituted with neutrally charged alan

277 lu-213 with alanine induced retention of the MERS-CoV M in the ER.

278 ic structure of the N-terminal domain of the MERS-CoV nucleocapsid protein (MERS-CoV N-NTD).

279 that contained the MERS-CoV S1 domain of the MERS-CoV S protein fused to the RABV G protein C terminu

280 Infections are initiated via binding of the MERS-CoV spike (S) glycoprotein to sialosides and dipept

281 neered a synthetic DNA vaccine targeting the MERS coronavirus Spike (S) protein, the major surface an

282 ular localization analyses revealed that the MERS-CoV M protein is retained intracellularly in the tr

283 glycosylation site that acts as a barrier to MERS-CoV infection.

284 ating that RLR signaling also contributed to MERS-CoV-induced proinflammatory response.

285 ectedly more resistant than hDPP4+/- mice to MERS-CoV infection, as judged by increased LD50, reduced

286 Additionally, the resistance to MERS-CoV infection directly correlated with increased se

287 mouse model to analyze the host response to MERS-CoV infection using immunological assays and transc

288 ed drugs for this use for a fast response to MERS-CoV outbreaks.

289 o evidence of the potential for RDV to treat MERS-CoV infections.

290 d high-resolution structures of the trimeric MERS-CoV S ectodomain in complex with G4, a stem-directe

291 To understand MERS-CoV engagement of sialylated receptors, we determin

292 flammatory cascade in human macrophages upon MERS-CoV infection.

293 ay with human erythrocytes and intact virus, MERS-CoV Sia-binding activity was assigned to S subdomai

294 for use in animals and humans in areas where MERS-CoV is endemic.

295 We infected cells from Eptesicus fuscus with MERS-CoV and maintained them in culture for at least 126

296 pulmonary manifestations when infected with MERS-CoV would advance the field.

297 at cells that are persistently infected with MERS-CoV.

298 d both vaccinated mice and control mice with MERS-CoV after adenovirus transduction of the human dipe

299 Nine camel workers with MERS-CoV antibodies and 43 workers without antibodies we

300 derstanding viral deISGylase activity within MERS-CoV and other CoVs.IMPORTANCE Coronaviruses, such a